295 related articles for article (PubMed ID: 34319509)
1. Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses.
Ali S; Xia Q; Muhammad T; Liu L; Meng X; Bars-Cortina D; Khan AA; Huang Y; Dong L
Stem Cell Rev Rep; 2022 Feb; 18(2):523-543. PubMed ID: 34319509
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of oncolytic viruses and stem cells in gene therapy: Should they be integrated?
Tahir M; Ahmad N; Lei D; Ali S
Drug Discov Today; 2022 Aug; 27(8):2244-2251. PubMed ID: 35351608
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stem cells loaded with Ad5-Ki67/IL-15 enhance oncolytic adenovirotherapy in experimental glioblastoma.
Wang P; Zhang J; Zhang Q; Liu F
Biomed Pharmacother; 2023 Jan; 157():114035. PubMed ID: 36434955
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy.
Mahasa KJ; de Pillis L; Ouifki R; Eladdadi A; Maini P; Yoon AR; Yun CO
Sci Rep; 2020 Jan; 10(1):425. PubMed ID: 31949228
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies.
Shah S
Med Sci (Basel); 2023 Dec; 12(1):. PubMed ID: 38249077
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.
Parker Kerrigan BC; Shimizu Y; Andreeff M; Lang FF
Cytotherapy; 2017 Apr; 19(4):445-457. PubMed ID: 28233640
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer.
Babaei A; Soleimanjahi H; Soleimani M; Arefian E
Biochem Pharmacol; 2021 Aug; 190():114644. PubMed ID: 34090878
[TBL] [Abstract][Full Text] [Related]
8. Intraarterial delivery of virotherapy for glioblastoma.
Srinivasan VM; Lang FF; Kan P
Neurosurg Focus; 2021 Feb; 50(2):E7. PubMed ID: 33524944
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cell plasticity in glioblastoma multiforme: a perspective on future directions in oncolytic virotherapy.
Kim DS
Future Oncol; 2020 Oct; 16(28):2251-2264. PubMed ID: 32744059
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses.
Hadryś A; Sochanik A; McFadden G; Jazowiecka-Rakus J
Eur J Pharmacol; 2020 May; 874():172991. PubMed ID: 32044323
[TBL] [Abstract][Full Text] [Related]
12. Directing systemic oncolytic viral delivery to tumors via carrier cells.
Nakashima H; Kaur B; Chiocca EA
Cytokine Growth Factor Rev; 2010; 21(2-3):119-26. PubMed ID: 20226717
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors.
Yoon AR; Rivera-Cruz C; Gimble JM; Yun CO; Figueiredo ML
Mol Ther Oncolytics; 2022 Jun; 25():78-97. PubMed ID: 35434272
[TBL] [Abstract][Full Text] [Related]
14. Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.
Petrov I; Gentschev I; Vyalkova A; Elashry MI; Klymiuk MC; Arnhold S; Szalay AA
Viruses; 2020 Jul; 12(7):. PubMed ID: 32664672
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in targeting cancer stem cells using oncolytic viruses.
Zhang YN; Wang SB; Song SS; Hu PY; Zhou YC; Mou YP; Mou XZ
Biotechnol Lett; 2020 Jun; 42(6):865-874. PubMed ID: 32166558
[TBL] [Abstract][Full Text] [Related]
16. A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus.
Bolontrade MF; Sganga L; Piaggio E; Viale DL; Sorrentino MA; Robinson A; Sevlever G; García MG; Mazzolini G; Podhajcer OL
Stem Cells Dev; 2012 Sep; 21(14):2689-702. PubMed ID: 22462538
[TBL] [Abstract][Full Text] [Related]
17. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
[TBL] [Abstract][Full Text] [Related]
18. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
[TBL] [Abstract][Full Text] [Related]
19. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
[TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study.
García-Castro J; Alemany R; Cascalló M; Martínez-Quintanilla J; Arriero Mdel M; Lassaletta A; Madero L; Ramírez M
Cancer Gene Ther; 2010 Jul; 17(7):476-83. PubMed ID: 20168350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
